30.10.2017 – 17:53

BB Biotech AG

DGAP-News: BB Biotech statement on MiFID II

DGAP-News: BB BIOTECH AG / Key word(s): Miscellaneous
BB Biotech statement on MiFID II (news with additional features)

30.10.2017 / 17:40
The issuer is solely responsible for the content of this announcement.

--------------------------------------------------------------------------------
Media Release of October 30, 2017

BB Biotech statement on MiFID II
 

Under the European Union's new Markets in Financial Instruments Directive MiFID
II that enters into effect at the beginning of 2018, financial services
providers will be required to provide clients with a transparent disclosure of
research costs and state how those costs will be absorbed. Bellevue Asset
Management, the company retained by BB Biotech, will absorb the costs incurred
for research and will not pass them onto its shareholders.
 

For further information:
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland
Tanja Chicherio, Tel. +41 44 267 67 07,tch@bellevue.ch
www.bbbiotech.com
 

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and
is one of the world's largest investors in this sector. BB Biotech is listed in
Switzerland, Germany and Italy. Its investments are focused on listed companies
that are developing and commercializing novel medical treatments and cures. BB
Biotech's investment selection process is guided by the fundamental research and
analysis of physicians and molecular biologists. Its Board of Directors has many
years of experience in industry and science.
--------------------------------------------------------------------------------
Additional features:

Document:http://n.eqs.com/c/fncls.ssp?u=WCDJYRBCMA
Document title: Media release

--------------------------------------------------------------------------------
30.10.2017  Dissemination of a Corporate News, transmitted by DGAP - a service
of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
--------------------------------------------------------------------------------

Language: English

Company:  BB BIOTECH AG

          Schwertstrasse 6

          8200 Schaffhausen

          Switzerland

Phone:    +41 52 624 08 45

E-mail:    info@bbbiotech.com

Internet: www.bbbiotech.ch

ISIN:     CH0038389992

WKN:      A0NFN3

Listed:   Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial
Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX



 

End of News DGAP News Service

--------------------------------------------------------------------------------

623749  30.10.2017